Femasys is a biomedical company focused on transforming women's healthcare by developing solutions to address severely underserved areas. Co. operates as one segment and is focused on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility issues. FemBloc® (FemBloc), Co.'s solution for permanent birth control, is based on Co.'s non-surgical platform technology. FemChec® Pressure Management Device evaluates the women's fallopian tubes after a FemBloc procedure and is part of the FemBloc validation study. FemCerv® Endocervical Sampler is designed to collect a complete, non-contaminated cervical tissue sample. The FEMY stock yearly return is shown above.
The yearly return on the FEMY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FEMY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|